Authors
Latest:
Ocular Toxicities of MEK Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysisJing Han, MD, and colleagues examine the prevalence and characteristics of ocular toxicities associated with MEK inhibition.
Latest:
Oncology Peer Review On-The-Go: Cancer-Related Fatigue Outcome Measures in Integrative OncologyAuthors Dori Beeler, PhD; Shelley Wang, MD, MPH; and Viraj A. Master, MD, PhD, spoke with CancerNetwork® about a review article on cancer-related fatigue published in the journal ONCOLOGY®.
Latest:
Closing Remarks on the Future of Treating HER2+ Metastatic Breast CancerThought leaders in breast oncology share closing remarks about the future management of HER2+ BC with brain metastases with key insights on unmet needs and evolving treatment approaches.
Latest:
Cross Q&A: Isa + KD in Relapsed/Refractory MM and Biochemical vs Clinical ProgressionIn the final cross Q&A session from the multiple myeloma module, panelists discuss implications of IKEMA and consider the importance of biochemical versus clinical progression.
Latest:
Oncology Peer Review On-The-Go: Cancer-Related Fatigue Outcome Measures in Integrative OncologyAuthors Dori Beeler, PhD; Shelley Wang, MD, MPH; and Viraj A. Master, MD, PhD, spoke with CancerNetwork® about a review article on cancer-related fatigue published in the journal ONCOLOGY®.
Latest:
Expert Commentary on the Product Profile of Lazertinib in NSCLCJenan Dailey, PharmD, BCAP, spoke about the approval of lazertinib plus amivantamab as first-line treatment for patients with locally advanced or metastatic NSCLC.
Latest:
Current Treatment of Peripheral T-cell LymphomaThis review article written by Robert Stuver, MD, et al, reviews current and available treatments for peripheral T-cell lymphoma.
Latest:
Advancing CML Management Towards an Ideal Patient JourneyThe panel concludes its discussion with insights on challenges and unmet needs in the CML treatment landscape, highlighting ways to better support patients and caregivers.
Latest:
Strategies for Overcoming Disparities for Patients With Hematologic Malignancies and for Improving Enrollment on Clinical TrialsA multitude of factors contributes to cancer disparities. Addressing these disparities among racial/ethnic minority populations with blood cancers requires multilevel models of the interactions between relevant factors and the performance of translational research that uses knowledge of cancer biology to develop and test the feasibility of interventions that can impact human endpoints. To be effective, efforts should be made to advance these research findings to applications that can transform clinical practice and health care delivery. We reviewed the literature to define a framework for overcoming disparities for patients with hematologic malignancies and to improve patient enrollment in clinical trials.
Latest:
Hereditary Renal Tumor Syndromes and the Use of mTOR InhibitorsA 47-year-old woman with a history of drug-resistant epilepsy during childhood presented to the emergency department with sudden dyspnea and chest pain. Upon admission, her oxygen saturation was 88%.
Latest:
Emergency Fertility Preservation in a Young Woman With Non-Hodgkin LymphomaA nulliparous woman, age 25 years, had received a diagnosis of non-Hodgkin lymphoma and now presented with stage IIA diffuse large B-cell lymphoma. Due to potential risks of chemotherapy-induced gonadotoxicity and subsequent iatrogenic premature ovarian failure and fertility loss, the patient was referred to the reproductive medicine department for fertility preservation counseling and further management.
Latest:
Recruiting Has Begun in Trial to Determine Magrolimab Efficacy in R/R AMLA phase 2 study has begun recruiting patients with relapsed/refractory acute myeloid leukemia to test the efficacy of magrolimab.
Latest:
Phillip S. Low, PhD, Discusses Next Steps in Research of 177Lu-PSMA-617 for mCRPC and Other CancersPhillip S. Low, PhD, spoke about what the future holds for treatments like 177Lu-PSMA-617 being developed for patients with prostate cancer.
Latest:
Strategies for Overcoming Disparities for Patients With Hematologic Malignancies and for Improving Enrollment on Clinical TrialsA multitude of factors contributes to cancer disparities. Addressing these disparities among racial/ethnic minority populations with blood cancers requires multilevel models of the interactions between relevant factors and the performance of translational research that uses knowledge of cancer biology to develop and test the feasibility of interventions that can impact human endpoints. To be effective, efforts should be made to advance these research findings to applications that can transform clinical practice and health care delivery. We reviewed the literature to define a framework for overcoming disparities for patients with hematologic malignancies and to improve patient enrollment in clinical trials.
Latest:
Recap: Recent Updates in the Treatment of Nonmetastatic Castration-Resistant Prostate CancerAaron Berger, MD, discussed updates in the treatment of nonmetastatic castration-resistant prostate cancer.
Latest:
Expert Commentary on the Product Profile of Tislelizumab in Advanced Esophageal CancerKrystal Preston, PharmD, BCPS, discussed the use and administration of tislelizumab for patients with resectable or metastatic esophageal squamous cell carcinoma.
Latest:
Emergency Fertility Preservation in a Young Woman With Non-Hodgkin LymphomaA nulliparous woman, age 25 years, had received a diagnosis of non-Hodgkin lymphoma and now presented with stage IIA diffuse large B-cell lymphoma. Due to potential risks of chemotherapy-induced gonadotoxicity and subsequent iatrogenic premature ovarian failure and fertility loss, the patient was referred to the reproductive medicine department for fertility preservation counseling and further management.
Latest:
Jakubowiak on Future Promise of Cilta-Cel Across Settings in Multiple Myeloma at 2021 ASHLooking forward, Andrzej Jakubowiak, MD, PhD, anticipates CAR T-cell therapy with ciltacabtagene autoleucel will establish its place across various indications for multiple myeloma.
